Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Trial Profile

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Idalopirdine (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARSHINE
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 09 Jan 2018 Results of pooled data from three trial (NCT01955161, NCT02006641 and NCT02006654) assessing whether idalopirdine is effective for symptomatic treatment of mild to moderate AD, were published in the JAMA: the Journal of the American Medical Association.
    • 20 Jul 2017 Results (n=2525) from STAR Phase III Program (NCT01955161, NCT02006641, NCT02006654), presented at the Alzheimer's Association International Conference 2017.
    • 23 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top